Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника: метаанализ контролируемых исследований
Эффективность включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника: метаанализ контролируемых исследований
Андреев Д.Н., Кучерявый Ю.А., Черемушкин С.В., Маев И.В. Эффективность включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника: метаанализ контролируемых исследований. Consilium Medicum. 2020; 22 (8): 27–31. DOI: 10.26442/20751753.2020.8.200194
DOI: 10.26442/20751753.2020.8.200194
________________________________________________
DOI: 10.26442/20751753.2020.8.200194
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Систематизация данных об эффективности включения масляной кислоты в схемы спазмолитической терапии синдрома раздраженного кишечника (СРК) в рамках метаанализа.
Методы. Поиск исследований проводился в электронных базах данных MEDLINE/PubMed, EMBASE, Cochrane, Российский индекс научного цитирования до июня 2020 г. Все контролируемые исследования, сравнивающие эффективность купирования абдоминальной боли у пациентов с СРК при применении комбинации масляной кислоты и стандартной спазмолитической терапии, включались в итоговый анализ.
Результаты. Нами были отобраны 8 контролируемых исследований (все из России) с участием 708 пациентов (412 – в группах с комбинированной терапией масляной кислотой и спазмолитиком; 296 – в группах с монотерапией спазмолитиком). Обобщенная эффективность купирования абдоминальной боли в группах комбинированной терапии составила 76,31% (95% доверительный интервал – ДИ 71,947–80,298), тогда как в группах с монотерапией – 33,58% (95% ДИ 28,294–39,199). Метаанализ показал, что добавление масляной кислоты к спазмолитической терапии достоверно повышает эффективность достижения полного регресса абдоминальной боли у пациентов с СРК (отношение шансов 5,995, 95% ДИ 4,282–8,395, p<0,001) в сравнении с монотерапией. Значимой гетерогенности между результатами исследований выявлено не было (p=0,3335; I2=12,38%).
Заключение. Настоящий метаанализ продемонстрировал, что включение масляной кислоты в схемы спазмолитической терапии СРК значимо увеличивает частоту купирования абдоминальной боли.
Ключевые слова: синдром раздраженного кишечника, масляная кислота, бутират, спазмолитик, боль, висцеральная гиперчувствительность.
Outcomes and methods. Searching for studies was performed using the MEDLINE / PubMed, EMBASE, Cochrane, Russian Science Citation Index electronic databases for a period till June 2020. All controlled studies comparing the effectiveness of abdominal pain relief in patients with IBS with a combination of butyric acid and standard antispasmodic therapy were included in the final analysis.
Results. We selected 8 controlled studies (all from Russia) which included totally 708 patients (412 in the groups of butyric acid and antispasmodic drug combined therapy; 296 in the groups of antispasmodic drug monotherapy). The overall effectiveness of abdominal pain relief in the combined therapy groups was 76.31% (95% confidence interval – CI 71.947–80.298), while in the monotherapy groups – 33,58% (95% CI 28.294–39.199). A meta-analysis showed that adding butyric acid to antispasmodic therapy significantly increases the effectiveness of achieving a complete regression of abdominal pain in patients with IBS (odds ratio 5.995, 95% CI 4.282–8.395, p<0,001) compared with monotherapy. There was no significant heterogeneity between the data of studies (p=0.3335; I2=12.38%).
Conclusions. This meta-analysis demonstrated that adding butyric acid to antispasmodic therapy regimens for IBS significantly increases the rate of abdominal pain relief.
Key words: irritable bowel syndrome, butyric acid, butyrate, antispasmodic drug, pain, visceral hypersensitivity.
Методы. Поиск исследований проводился в электронных базах данных MEDLINE/PubMed, EMBASE, Cochrane, Российский индекс научного цитирования до июня 2020 г. Все контролируемые исследования, сравнивающие эффективность купирования абдоминальной боли у пациентов с СРК при применении комбинации масляной кислоты и стандартной спазмолитической терапии, включались в итоговый анализ.
Результаты. Нами были отобраны 8 контролируемых исследований (все из России) с участием 708 пациентов (412 – в группах с комбинированной терапией масляной кислотой и спазмолитиком; 296 – в группах с монотерапией спазмолитиком). Обобщенная эффективность купирования абдоминальной боли в группах комбинированной терапии составила 76,31% (95% доверительный интервал – ДИ 71,947–80,298), тогда как в группах с монотерапией – 33,58% (95% ДИ 28,294–39,199). Метаанализ показал, что добавление масляной кислоты к спазмолитической терапии достоверно повышает эффективность достижения полного регресса абдоминальной боли у пациентов с СРК (отношение шансов 5,995, 95% ДИ 4,282–8,395, p<0,001) в сравнении с монотерапией. Значимой гетерогенности между результатами исследований выявлено не было (p=0,3335; I2=12,38%).
Заключение. Настоящий метаанализ продемонстрировал, что включение масляной кислоты в схемы спазмолитической терапии СРК значимо увеличивает частоту купирования абдоминальной боли.
Ключевые слова: синдром раздраженного кишечника, масляная кислота, бутират, спазмолитик, боль, висцеральная гиперчувствительность.
________________________________________________
Outcomes and methods. Searching for studies was performed using the MEDLINE / PubMed, EMBASE, Cochrane, Russian Science Citation Index electronic databases for a period till June 2020. All controlled studies comparing the effectiveness of abdominal pain relief in patients with IBS with a combination of butyric acid and standard antispasmodic therapy were included in the final analysis.
Results. We selected 8 controlled studies (all from Russia) which included totally 708 patients (412 in the groups of butyric acid and antispasmodic drug combined therapy; 296 in the groups of antispasmodic drug monotherapy). The overall effectiveness of abdominal pain relief in the combined therapy groups was 76.31% (95% confidence interval – CI 71.947–80.298), while in the monotherapy groups – 33,58% (95% CI 28.294–39.199). A meta-analysis showed that adding butyric acid to antispasmodic therapy significantly increases the effectiveness of achieving a complete regression of abdominal pain in patients with IBS (odds ratio 5.995, 95% CI 4.282–8.395, p<0,001) compared with monotherapy. There was no significant heterogeneity between the data of studies (p=0.3335; I2=12.38%).
Conclusions. This meta-analysis demonstrated that adding butyric acid to antispasmodic therapy regimens for IBS significantly increases the rate of abdominal pain relief.
Key words: irritable bowel syndrome, butyric acid, butyrate, antispasmodic drug, pain, visceral hypersensitivity.
Полный текст
Список литературы
1. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Андреев Д.Н. Синдром раздраженного кишечника с позиций современной фундаментальной и клинической медицины. М., 2019.
[Maev I.V., Cheremushkin S.V., Kucheryavyy Yu.A., Andreev D.N. Irritable bowel syndrome from the perspective of modern fundamental and clinical medicine. Moscow, 2019 (in Russian).]
2. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020. DOI: 10.1038/s41575-020-0286-8
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10 (7): 712–21.e4. DOI: 10.1016/j.cgh.2012.02.029
4. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One 2015; 10 (5): e0126982. DOI: 10.1371/journal.pone.0126982
5. Zielińska A, Sałaga M, Włodarczyk M, Fichna J. Chronic abdominal pain in irritable bowel syndrome – current and future therapies. Expert Rev Clin Pharmacol 2018; 11 (7): 729–39.
6. Mearin F, Lacy BE, Chang L et al. Bowel Disorders. Gastroenterology 2016: S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031
7. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (5): 76–93. DOI: 10.22416/1382-4376-2017-27-5-76-93
[Ivashkin V.T., Shelygin Y.A., Baranskaya Y.K. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (5): 76–93. DOI: 10.22416/1382-4376-2017-27-5-76-93 (in Russian).]
8. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3): 355–61. DOI: 10.1046/j.1365-2036.2001.00937.x
9. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313. DOI: 10.1136/bmj.a2313
10. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24 (21): 2211–35. DOI: 10.3748/wjg.v24.i21.2211
11. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013; 8 (6): 350–3. DOI: 10.5114/pg.2013.39917
12. Manrique Vergara D, González Sánchez ME. Short chain fatty acids (butyric acid) and intestinal diseases. Nutr Hosp 2017; 34 (Suppl. 4): 58–61. DOI: 10.20960/nh.1573
13. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15 (5): 474–9. DOI: 10.1097/MCO.0b013e32835665fa
14. Nozu T, Miyagishi S, Nozu R et al. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019; 9 (1): 19603. DOI: 10.1038/s41598-019-56132-4
15. Vanhoutvin SA, Troost FJ, Kilkens TO et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21 (9): 952–e76. DOI: 10.1111/j.1365-2982.2009.01324.x
16. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013; 15 (2): 204–9. DOI: 10.1111/j.1463-1318.2012.03152.x
17. Ардатская М.Д., Топчий Т.Б., Лощинина Ю.Н., Калашникова М.А. Клиническая эффективность масляной кислоты и инулина в купировании болевого синдрома у пациентов с синдромом раздраженной кишки. Лечащий врач. 2015; 12: 79–85.
[Ardatskaya M.D., Topchy TB, Loshchinina Yu.N., Kalashnikova M.A. Clinical efficacy of butyric acid and inulin in the relief of pain in patients with irritable bowel syndrome. Attending Doctor. 2015; 12: 79–85 (in Russian).]
18. Немцов В.И. Синдром раздраженной кишки (СРК): новые представления об этиопатогенезе и лечении. Лечащий врач. 2015; 6: 60–5.
[Nemtsov V.I. Irritable bowel syndrome (IBS): new insights into etiopathogenesis and treatment. Attending Doctor. 2015; 6: 60–5 (in Russian).]
19. Корочанская Н., Серикова С., Васькова Е. Комплексная медикаментозная терапия пациентов с разными типами синдрома раздраженной кишки. Врач. 2016; 6: 45–9.
[Korochanskaya N., Serikova S., Vaskova E. Complex drug therapy for patients with different types of irritable bowel syndrome. Doctor. 2016; 6: 45–9 (in Russian).]
20. Приходько Е.М., Цурцумия Д.Б., Селиверстов П.В. и др. Возможности современной терапии у пациентов с синдромом раздраженного кишечника. Лечащий врач. 2016; 8: 76–9.
[Prikhodko E.M., Tsurtsumiya D.B., Seliverstov P.V. et al. The possibilities of modern therapy in patients with irritable bowel syndrome. Attending Doctor. 2016; 8: 76–9 (in Russian).]
21. Сарсенбаева А., Смолягина А., Уфимцев К., Иванова Е. Синдром раздраженного кишечника: некоторые аспекты патогенеза и комплексной терапии. Врач. 2016; 10: 52–6.
[Sarsenbaeva A., Smolyagina A., Ufimtsev K., Ivanova E. Irritable bowel syndrome: some aspects of pathogenesis and complex therapy. Doctor. 2016; 10: 52–6 (in Russian).]
22. Козлова Н.М., Меринова Н.И. Эффективность применения комбинированного препарата масляной кислоты у пациентов с синдромом раздраженного кишечника. Лечащий врач. 2017; 4: 51–5.
[Kozlova N.M., Merinova N.I. The effectiveness of the combined preparation of butyric acid in patients with irritable bowel syndrome. Attending Doctor. 2017; 4: 51–5 (in Russian).]
23. Левченко С.В., Комиссаренко И.А., Голохвастова А.А. и др. Эффективность масляной кислоты и инулина у больных синдромом раздраженного кишечника: результаты многоцентрового исследования. Лечащий врач. 2018; 2: 53–60.
[Levchenko S.V., Komissarenko I.A., Golokhvastova A.A. et al. The effectiveness of butyric acid and inulin in patients with irritable bowel syndrome: results of a multicenter study. Attending Doctor. 2018; 2: 53–60 (in Russian).]
24. Бутова Е.Н. Оптимизация современной терапии пациентов с синдромом раздраженного кишечника. Лечащий врач. 2019; 7: 53–9.
[Butova E.N. Optimization of modern therapy for patients with irritable bowel syndrome. Attending Doctor. 2019; 7: 53–9 (in Russian).]
25. Oświęcimska J, Szymlak A, Roczniak W et al. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 2017; 62 (1): 17–30. DOI: 10.1016/j.advms.2016.11.001
26. Tarnowski W, Borycka-Kiciak K, Kiciak A. Outcome of treatment with butyric acid In irritable bowel syndrome – preliminary report. Gastroenterol Prakt 2011; 1: 43–8.
27. Андреев Д.Н., Дичева Д.Т. Нарушение проницаемости слизистой оболочки кишечника как фактор этиопатогенеза функциональных заболеваний желудочно-кишечного тракта. Мед. совет. 2020; 5: 87–95. DOI: 10.21518/2079-701X-2020-5-87-95
[Andreev D.N., Dicheva D.T. A breach in the intestinal permeability as a factor of etiopathogenesis of functional gastrointestinal diseases. Meditsinskiy sovet. 2020; 5: 87–95. DOI: 10.21518/2079-701X-2020-5-87-95 (in Russian).]
28. Ng QX, Soh AYS, Loke W et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018; 11: 345–9.
29. Bashashati M, Moossavi S, Cremon C et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30 (1). DOI: 10.1111/nmo.13192
30. Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract 2016; 2016: 2031480.
31. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132 (1): 26–37. DOI: 10.1053/j.gastro.2006.11.039
32. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 (4): 1425–34. DOI: 10.1053/j.gastro.2009.07.005
33. Zhang H, Du M, Yang Q, Zhu MJ. Butyrate suppresses murine mast cell proliferation and cytokine production through inhibiting histone deacetylase. J Nutr Biochem 2016; 27: 299–306. DOI: 10.1016/j.jnutbio.2015.09.020
34. Wang CC, Wu H, Lin FH et al. Sodium butyrate enhances intestinal integrity, inhibits mast cell activation, inflammatory mediator production and JNK signaling pathway in weaned pigs. Innate Immun 2018; 24 (1): 40–6. DOI: 10.1177/1753425917741970
35. Folkerts J, Redegeld F, Folkerts G et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy 2020. DOI: 10.1111/all.14254
36. Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr 2019; 59 (Suppl 1): S130–S152. DOI: 10.1080/10408398.2018.1542587
37. Miquel S, Martín R, Lashermes A et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci Rep 2016; 6: 19399. DOI: 10.1038/srep19399
38. Zhao K, Yu L, Wang X et al. Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (2): 216–23. DOI: 10.1093/abbs/gmx138
2. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020. DOI: 10.1038/s41575-020-0286-8
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10 (7): 712–21.e4. DOI: 10.1016/j.cgh.2012.02.029
4. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One 2015; 10 (5): e0126982. DOI: 10.1371/journal.pone.0126982
5. Zielińska A, Sałaga M, Włodarczyk M, Fichna J. Chronic abdominal pain in irritable bowel syndrome – current and future therapies. Expert Rev Clin Pharmacol 2018; 11 (7): 729–39.
6. Mearin F, Lacy BE, Chang L et al. Bowel Disorders. Gastroenterology 2016: S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031
7. Ivashkin V.T., Shelygin Y.A., Baranskaya Y.K. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (5): 76–93. DOI: 10.22416/1382-4376-2017-27-5-76-93 (in Russian).
8. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3): 355–61. DOI: 10.1046/j.1365-2036.2001.00937.x
9. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313. DOI: 10.1136/bmj.a2313
10. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24 (21): 2211–35. DOI: 10.3748/wjg.v24.i21.2211
11. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013; 8 (6): 350–3. DOI: 10.5114/pg.2013.39917
12. Manrique Vergara D, González Sánchez ME. Short chain fatty acids (butyric acid) and intestinal diseases. Nutr Hosp 2017; 34 (Suppl. 4): 58–61. DOI: 10.20960/nh.1573
13. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15 (5): 474–9. DOI: 10.1097/MCO.0b013e32835665fa
14. Nozu T, Miyagishi S, Nozu R et al. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019; 9 (1): 19603. DOI: 10.1038/s41598-019-56132-4
15. Vanhoutvin SA, Troost FJ, Kilkens TO et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21 (9): 952–e76. DOI: 10.1111/j.1365-2982.2009.01324.x
16. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013; 15 (2): 204–9. DOI: 10.1111/j.1463-1318.2012.03152.x
17. Ardatskaya M.D., Topchy TB, Loshchinina Yu.N., Kalashnikova M.A. Clinical efficacy of butyric acid and inulin in the relief of pain in patients with irritable bowel syndrome. Attending Doctor. 2015; 12: 79–85 (in Russian).
18. Nemtsov V.I. Irritable bowel syndrome (IBS): new insights into etiopathogenesis and treatment. Attending Doctor. 2015; 6: 60–5 (in Russian).
19. Korochanskaya N., Serikova S., Vaskova E. Complex drug therapy for patients with different types of irritable bowel syndrome. Doctor. 2016; 6: 45–9 (in Russian).
20. Prikhodko E.M., Tsurtsumiya D.B., Seliverstov P.V. et al. The possibilities of modern therapy in patients with irritable bowel syndrome. Attending Doctor. 2016; 8: 76–9 (in Russian).
21. Sarsenbaeva A., Smolyagina A., Ufimtsev K., Ivanova E. Irritable bowel syndrome: some aspects of pathogenesis and complex therapy. Doctor. 2016; 10: 52–6 (in Russian).
22. Kozlova N.M., Merinova N.I. The effectiveness of the combined preparation of butyric acid in patients with irritable bowel syndrome. Attending Doctor. 2017; 4: 51–5 (in Russian).
23. Levchenko S.V., Komissarenko I.A., Golokhvastova A.A. et al. The effectiveness of butyric acid and inulin in patients with irritable bowel syndrome: results of a multicenter study. Attending Doctor. 2018; 2: 53–60 (in Russian).
24. Butova E.N. Optimization of modern therapy for patients with irritable bowel syndrome. Attending Doctor. 2019; 7: 53–9 (in Russian).
25. Oświęcimska J, Szymlak A, Roczniak W et al. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 2017; 62 (1): 17–30. DOI: 10.1016/j.advms.2016.11.001
26. Tarnowski W, Borycka-Kiciak K, Kiciak A. Outcome of treatment with butyric acid In irritable bowel syndrome – preliminary report. Gastroenterol Prakt 2011; 1: 43–8.
27. Andreev D.N., Dicheva D.T. A breach in the intestinal permeability as a factor of etiopathogenesis of functional gastrointestinal diseases. Meditsinskiy sovet. 2020; 5: 87–95. DOI: 10.21518/2079-701X-2020-5-87-95 (in Russian).
28. Ng QX, Soh AYS, Loke W et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018; 11: 345–9.
29. Bashashati M, Moossavi S, Cremon C et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30 (1). DOI: 10.1111/nmo.13192
30. Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract 2016; 2016: 2031480.
31. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132 (1): 26–37. DOI: 10.1053/j.gastro.2006.11.039
32. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 (4): 1425–34. DOI: 10.1053/j.gastro.2009.07.005
33. Zhang H, Du M, Yang Q, Zhu MJ. Butyrate suppresses murine mast cell proliferation and cytokine production through inhibiting histone deacetylase. J Nutr Biochem 2016; 27: 299–306. DOI: 10.1016/j.jnutbio.2015.09.020
34. Wang CC, Wu H, Lin FH et al. Sodium butyrate enhances intestinal integrity, inhibits mast cell activation, inflammatory mediator production and JNK signaling pathway in weaned pigs. Innate Immun 2018; 24 (1): 40–6. DOI: 10.1177/1753425917741970
35. Folkerts J, Redegeld F, Folkerts G et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy 2020. DOI: 10.1111/all.14254
36. Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr 2019; 59 (Suppl 1): S130–S152. DOI: 10.1080/10408398.2018.1542587
37. Miquel S, Martín R, Lashermes A et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci Rep 2016; 6: 19399. DOI: 10.1038/srep19399
38. Zhao K, Yu L, Wang X et al. Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (2): 216–23. DOI: 10.1093/abbs/gmx138
[Maev I.V., Cheremushkin S.V., Kucheryavyy Yu.A., Andreev D.N. Irritable bowel syndrome from the perspective of modern fundamental and clinical medicine. Moscow, 2019 (in Russian).]
2. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020. DOI: 10.1038/s41575-020-0286-8
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10 (7): 712–21.e4. DOI: 10.1016/j.cgh.2012.02.029
4. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One 2015; 10 (5): e0126982. DOI: 10.1371/journal.pone.0126982
5. Zielińska A, Sałaga M, Włodarczyk M, Fichna J. Chronic abdominal pain in irritable bowel syndrome – current and future therapies. Expert Rev Clin Pharmacol 2018; 11 (7): 729–39.
6. Mearin F, Lacy BE, Chang L et al. Bowel Disorders. Gastroenterology 2016: S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031
7. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (5): 76–93. DOI: 10.22416/1382-4376-2017-27-5-76-93
[Ivashkin V.T., Shelygin Y.A., Baranskaya Y.K. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (5): 76–93. DOI: 10.22416/1382-4376-2017-27-5-76-93 (in Russian).]
8. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3): 355–61. DOI: 10.1046/j.1365-2036.2001.00937.x
9. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313. DOI: 10.1136/bmj.a2313
10. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24 (21): 2211–35. DOI: 10.3748/wjg.v24.i21.2211
11. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013; 8 (6): 350–3. DOI: 10.5114/pg.2013.39917
12. Manrique Vergara D, González Sánchez ME. Short chain fatty acids (butyric acid) and intestinal diseases. Nutr Hosp 2017; 34 (Suppl. 4): 58–61. DOI: 10.20960/nh.1573
13. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15 (5): 474–9. DOI: 10.1097/MCO.0b013e32835665fa
14. Nozu T, Miyagishi S, Nozu R et al. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019; 9 (1): 19603. DOI: 10.1038/s41598-019-56132-4
15. Vanhoutvin SA, Troost FJ, Kilkens TO et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21 (9): 952–e76. DOI: 10.1111/j.1365-2982.2009.01324.x
16. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013; 15 (2): 204–9. DOI: 10.1111/j.1463-1318.2012.03152.x
17. Ардатская М.Д., Топчий Т.Б., Лощинина Ю.Н., Калашникова М.А. Клиническая эффективность масляной кислоты и инулина в купировании болевого синдрома у пациентов с синдромом раздраженной кишки. Лечащий врач. 2015; 12: 79–85.
[Ardatskaya M.D., Topchy TB, Loshchinina Yu.N., Kalashnikova M.A. Clinical efficacy of butyric acid and inulin in the relief of pain in patients with irritable bowel syndrome. Attending Doctor. 2015; 12: 79–85 (in Russian).]
18. Немцов В.И. Синдром раздраженной кишки (СРК): новые представления об этиопатогенезе и лечении. Лечащий врач. 2015; 6: 60–5.
[Nemtsov V.I. Irritable bowel syndrome (IBS): new insights into etiopathogenesis and treatment. Attending Doctor. 2015; 6: 60–5 (in Russian).]
19. Корочанская Н., Серикова С., Васькова Е. Комплексная медикаментозная терапия пациентов с разными типами синдрома раздраженной кишки. Врач. 2016; 6: 45–9.
[Korochanskaya N., Serikova S., Vaskova E. Complex drug therapy for patients with different types of irritable bowel syndrome. Doctor. 2016; 6: 45–9 (in Russian).]
20. Приходько Е.М., Цурцумия Д.Б., Селиверстов П.В. и др. Возможности современной терапии у пациентов с синдромом раздраженного кишечника. Лечащий врач. 2016; 8: 76–9.
[Prikhodko E.M., Tsurtsumiya D.B., Seliverstov P.V. et al. The possibilities of modern therapy in patients with irritable bowel syndrome. Attending Doctor. 2016; 8: 76–9 (in Russian).]
21. Сарсенбаева А., Смолягина А., Уфимцев К., Иванова Е. Синдром раздраженного кишечника: некоторые аспекты патогенеза и комплексной терапии. Врач. 2016; 10: 52–6.
[Sarsenbaeva A., Smolyagina A., Ufimtsev K., Ivanova E. Irritable bowel syndrome: some aspects of pathogenesis and complex therapy. Doctor. 2016; 10: 52–6 (in Russian).]
22. Козлова Н.М., Меринова Н.И. Эффективность применения комбинированного препарата масляной кислоты у пациентов с синдромом раздраженного кишечника. Лечащий врач. 2017; 4: 51–5.
[Kozlova N.M., Merinova N.I. The effectiveness of the combined preparation of butyric acid in patients with irritable bowel syndrome. Attending Doctor. 2017; 4: 51–5 (in Russian).]
23. Левченко С.В., Комиссаренко И.А., Голохвастова А.А. и др. Эффективность масляной кислоты и инулина у больных синдромом раздраженного кишечника: результаты многоцентрового исследования. Лечащий врач. 2018; 2: 53–60.
[Levchenko S.V., Komissarenko I.A., Golokhvastova A.A. et al. The effectiveness of butyric acid and inulin in patients with irritable bowel syndrome: results of a multicenter study. Attending Doctor. 2018; 2: 53–60 (in Russian).]
24. Бутова Е.Н. Оптимизация современной терапии пациентов с синдромом раздраженного кишечника. Лечащий врач. 2019; 7: 53–9.
[Butova E.N. Optimization of modern therapy for patients with irritable bowel syndrome. Attending Doctor. 2019; 7: 53–9 (in Russian).]
25. Oświęcimska J, Szymlak A, Roczniak W et al. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 2017; 62 (1): 17–30. DOI: 10.1016/j.advms.2016.11.001
26. Tarnowski W, Borycka-Kiciak K, Kiciak A. Outcome of treatment with butyric acid In irritable bowel syndrome – preliminary report. Gastroenterol Prakt 2011; 1: 43–8.
27. Андреев Д.Н., Дичева Д.Т. Нарушение проницаемости слизистой оболочки кишечника как фактор этиопатогенеза функциональных заболеваний желудочно-кишечного тракта. Мед. совет. 2020; 5: 87–95. DOI: 10.21518/2079-701X-2020-5-87-95
[Andreev D.N., Dicheva D.T. A breach in the intestinal permeability as a factor of etiopathogenesis of functional gastrointestinal diseases. Meditsinskiy sovet. 2020; 5: 87–95. DOI: 10.21518/2079-701X-2020-5-87-95 (in Russian).]
28. Ng QX, Soh AYS, Loke W et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018; 11: 345–9.
29. Bashashati M, Moossavi S, Cremon C et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30 (1). DOI: 10.1111/nmo.13192
30. Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract 2016; 2016: 2031480.
31. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132 (1): 26–37. DOI: 10.1053/j.gastro.2006.11.039
32. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 (4): 1425–34. DOI: 10.1053/j.gastro.2009.07.005
33. Zhang H, Du M, Yang Q, Zhu MJ. Butyrate suppresses murine mast cell proliferation and cytokine production through inhibiting histone deacetylase. J Nutr Biochem 2016; 27: 299–306. DOI: 10.1016/j.jnutbio.2015.09.020
34. Wang CC, Wu H, Lin FH et al. Sodium butyrate enhances intestinal integrity, inhibits mast cell activation, inflammatory mediator production and JNK signaling pathway in weaned pigs. Innate Immun 2018; 24 (1): 40–6. DOI: 10.1177/1753425917741970
35. Folkerts J, Redegeld F, Folkerts G et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy 2020. DOI: 10.1111/all.14254
36. Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr 2019; 59 (Suppl 1): S130–S152. DOI: 10.1080/10408398.2018.1542587
37. Miquel S, Martín R, Lashermes A et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci Rep 2016; 6: 19399. DOI: 10.1038/srep19399
38. Zhao K, Yu L, Wang X et al. Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (2): 216–23. DOI: 10.1093/abbs/gmx138
________________________________________________
2. Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020. DOI: 10.1038/s41575-020-0286-8
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10 (7): 712–21.e4. DOI: 10.1016/j.cgh.2012.02.029
4. Korterink JJ, Diederen K, Benninga MA, Tabbers MM. Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis. PLoS One 2015; 10 (5): e0126982. DOI: 10.1371/journal.pone.0126982
5. Zielińska A, Sałaga M, Włodarczyk M, Fichna J. Chronic abdominal pain in irritable bowel syndrome – current and future therapies. Expert Rev Clin Pharmacol 2018; 11 (7): 729–39.
6. Mearin F, Lacy BE, Chang L et al. Bowel Disorders. Gastroenterology 2016: S0016-5085(16)00222-5. DOI: 10.1053/j.gastro.2016.02.031
7. Ivashkin V.T., Shelygin Y.A., Baranskaya Y.K. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017; 27 (5): 76–93. DOI: 10.22416/1382-4376-2017-27-5-76-93 (in Russian).
8. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15 (3): 355–61. DOI: 10.1046/j.1365-2036.2001.00937.x
9. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313. DOI: 10.1136/bmj.a2313
10. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24 (21): 2211–35. DOI: 10.3748/wjg.v24.i21.2211
11. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol 2013; 8 (6): 350–3. DOI: 10.5114/pg.2013.39917
12. Manrique Vergara D, González Sánchez ME. Short chain fatty acids (butyric acid) and intestinal diseases. Nutr Hosp 2017; 34 (Suppl. 4): 58–61. DOI: 10.20960/nh.1573
13. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care 2012; 15 (5): 474–9. DOI: 10.1097/MCO.0b013e32835665fa
14. Nozu T, Miyagishi S, Nozu R et al. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Sci Rep 2019; 9 (1): 19603. DOI: 10.1038/s41598-019-56132-4
15. Vanhoutvin SA, Troost FJ, Kilkens TO et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21 (9): 952–e76. DOI: 10.1111/j.1365-2982.2009.01324.x
16. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013; 15 (2): 204–9. DOI: 10.1111/j.1463-1318.2012.03152.x
17. Ardatskaya M.D., Topchy TB, Loshchinina Yu.N., Kalashnikova M.A. Clinical efficacy of butyric acid and inulin in the relief of pain in patients with irritable bowel syndrome. Attending Doctor. 2015; 12: 79–85 (in Russian).
18. Nemtsov V.I. Irritable bowel syndrome (IBS): new insights into etiopathogenesis and treatment. Attending Doctor. 2015; 6: 60–5 (in Russian).
19. Korochanskaya N., Serikova S., Vaskova E. Complex drug therapy for patients with different types of irritable bowel syndrome. Doctor. 2016; 6: 45–9 (in Russian).
20. Prikhodko E.M., Tsurtsumiya D.B., Seliverstov P.V. et al. The possibilities of modern therapy in patients with irritable bowel syndrome. Attending Doctor. 2016; 8: 76–9 (in Russian).
21. Sarsenbaeva A., Smolyagina A., Ufimtsev K., Ivanova E. Irritable bowel syndrome: some aspects of pathogenesis and complex therapy. Doctor. 2016; 10: 52–6 (in Russian).
22. Kozlova N.M., Merinova N.I. The effectiveness of the combined preparation of butyric acid in patients with irritable bowel syndrome. Attending Doctor. 2017; 4: 51–5 (in Russian).
23. Levchenko S.V., Komissarenko I.A., Golokhvastova A.A. et al. The effectiveness of butyric acid and inulin in patients with irritable bowel syndrome: results of a multicenter study. Attending Doctor. 2018; 2: 53–60 (in Russian).
24. Butova E.N. Optimization of modern therapy for patients with irritable bowel syndrome. Attending Doctor. 2019; 7: 53–9 (in Russian).
25. Oświęcimska J, Szymlak A, Roczniak W et al. New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 2017; 62 (1): 17–30. DOI: 10.1016/j.advms.2016.11.001
26. Tarnowski W, Borycka-Kiciak K, Kiciak A. Outcome of treatment with butyric acid In irritable bowel syndrome – preliminary report. Gastroenterol Prakt 2011; 1: 43–8.
27. Andreev D.N., Dicheva D.T. A breach in the intestinal permeability as a factor of etiopathogenesis of functional gastrointestinal diseases. Meditsinskiy sovet. 2020; 5: 87–95. DOI: 10.21518/2079-701X-2020-5-87-95 (in Russian).
28. Ng QX, Soh AYS, Loke W et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018; 11: 345–9.
29. Bashashati M, Moossavi S, Cremon C et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30 (1). DOI: 10.1111/nmo.13192
30. Lee KN, Lee OY. The Role of Mast Cells in Irritable Bowel Syndrome. Gastroenterol Res Pract 2016; 2016: 2031480.
31. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132 (1): 26–37. DOI: 10.1053/j.gastro.2006.11.039
32. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 (4): 1425–34. DOI: 10.1053/j.gastro.2009.07.005
33. Zhang H, Du M, Yang Q, Zhu MJ. Butyrate suppresses murine mast cell proliferation and cytokine production through inhibiting histone deacetylase. J Nutr Biochem 2016; 27: 299–306. DOI: 10.1016/j.jnutbio.2015.09.020
34. Wang CC, Wu H, Lin FH et al. Sodium butyrate enhances intestinal integrity, inhibits mast cell activation, inflammatory mediator production and JNK signaling pathway in weaned pigs. Innate Immun 2018; 24 (1): 40–6. DOI: 10.1177/1753425917741970
35. Folkerts J, Redegeld F, Folkerts G et al. Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy 2020. DOI: 10.1111/all.14254
36. Fu X, Liu Z, Zhu C et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr 2019; 59 (Suppl 1): S130–S152. DOI: 10.1080/10408398.2018.1542587
37. Miquel S, Martín R, Lashermes A et al. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. Sci Rep 2016; 6: 19399. DOI: 10.1038/srep19399
38. Zhao K, Yu L, Wang X et al. Clostridium butyricum regulates visceral hypersensitivity of irritable bowel syndrome by inhibiting colonic mucous low grade inflammation through its action on NLRP6. Acta Biochim Biophys Sin (Shanghai) 2018; 50 (2): 216–23. DOI: 10.1093/abbs/gmx138
Авторы
Д.Н. Андреев*, Ю.А. Кучерявый, С.В. Черемушкин, И.В. Маев
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*dna-mit8@mail.ru
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*dna-mit8@mail.ru
ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия
*dna-mit8@mail.ru
________________________________________________
Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
*dna-mit8@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.